This information is for healthcare professionals, however not intended for UK or Ireland audience.
Are you a healthcare professional (not UK or Ireland)?
About hATTR
About hATTR
Hereditary transthyretin amyloidosis is a rapidly progressive and life-shortening disease
Hereditary transthyretin amyloidosis is a rapidly progressive and life-shortening disease
hATTR is a complex, unpredictable multisystem, multiorgan disease with significant impact on quality of life.1,2 If untreated, hATTR is invariably fatal in less than two decades.2
Read more
References:
- Yarlas A, Gertz MA et al., Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve. 2019 Aug;60(2):169-175.
- Monteiro c, Mesgazardeh JS et a,. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 2019 Jun 20;4(12):e126526.
- Adams D, Ando Y et al., J Neurol. 2021 Jun;268(6):2109-212.
- Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(suppl 7):S107–S112.
- Amyloidosis Foundation. Understanding the patient voice in hereditary transthyretin-mediated amyloidosis (ATTR amyloidosis). Available at: https://www.amyloidosissupport.org/support_groups/fam_isabell_attr.pdf. Accessed April 2020.